Mostrando 10 resultados de: 161
Publisher
Pharmacogenomics(24)
Pharmacogenomics Journal(20)
Drug Metabolism and Drug Interactions(11)
Drug Metabolism and Personalized Therapy(8)
European Journal of Clinical Pharmacology(8)
Área temáticas
Farmacología y terapéutica(115)
Enfermedades(74)
Bioquímica(38)
Medicina y salud(37)
Fisiología humana(30)
A Code of Ethics for Ethicists: What Would Pierre Bourdieu Say? “Do Not Misuse Social Capital in the Age of Consortia Ethics”
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Dove E.S., Güngör K., Kılıç H., Özdemir V., Sardaş S., Vayena E., Yıldırım A.Fuentes:scopusA Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
ArticleAbstract: Background: The characterization of the first episode of psychosis and how it should be treated arePalabras claves:Antipsychotic, first episode psychosis, pharmacovigilance, polytherapy, psychotropic drugs, SchizophreniaAutores:Adrián LLerena, Aguilar E.J., Albacete A., Alonso-Solís A., Amoretti S., Baeza I., Balanzá-Martínez V., Bernardo M., Bioque M., Bobes J., Bulbena A., Butjosa A., Cabrera B., Castro-Fornieles J., Contreras F., Corripio I., Cuesta M.J., Díaz-Caneja M.C., Escartí M.J., García Bernardo E., García-Portilla M.P., Gassó P., González I., González-Pinto A., Grasa E., Hernandez M., Ibáñez Á., Lafuente A., Landín-Romero R., Lobo A., Mané A., Mas S., Mezquida G., Modrego F., Morales-Muñoz I., Parellada M., Rodriguez-Jimenez R., Ruiz P., Saiz-Ruiz J., Sánchez-Torres A.M., Sarró S., Segarra R., Tapia-Casellas C., Torrent C., Vieta E., Zabala Rabadán A.Fuentes:scopusA one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts
ArticleAbstract: This study of a cohort of 1-year treatment-compliant survivors of a suicide attempt examined for thePalabras claves:Autores:Adrián LLerena, Cortés-Martínez A., Courtet P., de Andrés F., Dubois J., Guillaume S., Kahn J.P., Leboyer M., Olié E., Penãs-Lledó E.M.Fuentes:scopusABCB1 gene polymorphisms and violent suicide attempt among survivors
ArticleAbstract: Introduction: Those suicide attempters that choose violent methods dramatically diminish the possibiPalabras claves:ABCB1, Suicide attempt, Violent suicide methodsAutores:Adrián LLerena, Courtet P., Delgado A., Guillaume S., Jaussent I., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCharacterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: Pharmacogenetic implications
ArticleAbstract: CYP2D6 codes for a protein that is vastly involved in the metabolism of various substances. This genPalabras claves:CYP2D6, CYP450, Metabolic profile, pharmacogenetics, Pharmacogenomics, polymorphism, Portuguese populationAutores:Adrián LLerena, Albuquerque J., Grazina M., Naranjo M.E.G., Ribeiro C.Fuentes:scopusClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update
ReviewAbstract: Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokiPalabras claves:Autores:Adrián LLerena, Callaghan J.T., Caudle K.E., Fohner A.E., Formea C.M., Gaedigk A., Huddart R., Karnes J.H., Klein T.E., Mintzer S., Phillips E.J., Rettie A.E., Somogyi A.A., Ta Michael Lee M., Whirl-Carrillo M.Fuentes:scopusClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors
ArticleAbstract: Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive aPalabras claves:Autores:Adrián LLerena, Bishop J.R., Caudle K.E., Chiulli D.L., Gaedigk A., Graham R.L., Hicks J.K., Ji Y., Klein T.E., Leckband S.G., Leeder J.S., Muller D.J., Sangkuhl K., Scott S.A., Skaar T.C., Stingl J.C.Fuentes:scopusClinical drug-drug interactions: Focus on venlafaxine
ReviewAbstract: Venlafaxine (VEN) is an antidepressant agent widely used nowadays as an alternative to selective serPalabras claves:Drug-drug interactions, pharmacodynamics, pharmacokinetics, VenlafaxineAutores:Adrián LLerena, Alves G., Falcao A.C., Magalhães P.Fuentes:scopusClinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusClinical pharmacology of drug metabolism and drug interactions: Clinical, interethnical and regulatory aspects
OtherAbstract:Palabras claves:Autores:Adrián LLerenaFuentes:scopus